Multiple sclerosis (Q28299151)

7 January 2021

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Age at disability milestones in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Natural history of multiple sclerosis with childhood onset.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Trends in survival and cause of death in Danish patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Affective disorders in multiple sclerosis. Review and recommendations for clinical research

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post‐partum relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Prospective study on the relationship between infections and multiple sclerosis exacerbations.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Association between parasite infection and immune responses in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Epidemiologic evidence for multiple sclerosis as an infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Sex ratio of multiple sclerosis in Canada: a longitudinal study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

On the Risk of Multiple Sclerosis According to Age at Immigration to South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Multiple sclerosis in Israel. Prevalence among immigrants and native inhabitants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Evidence for lower susceptibility to multiple sclerosis in Japanese-Americans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Multiple sclerosis among United Kingdom-born children of immigrants from the Indian subcontinent, Africa and the West Indies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Symptomatic Epstein-Barr virus infection and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Multiple sclerosis and Epstein-Barr virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

A functional and structural basis for TCR cross-reactivity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Parental smoking at home and the risk of childhood-onset multiple sclerosis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Cigarette smoking and the progression of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Environmental risk factors in multiple sclerosis aetiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Clinical concordance in sibling pairs with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Risks of multiple sclerosis in relatives of patients in Flanders, Belgium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Age-adjusted recurrence risks for relatives of patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

The familial nature of multiple sclerosis: Age-corrected empiric recurrence risks for children and siblings of patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Twin concordance and sibling recurrence rates in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

The British Isles survey of multiple sclerosis in twins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Multiple sclerosis in 54 twinships: concordance rate is independent of zygosity. French Research Group on Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Multiple sclerosis in twins from continental Italy and Sardinia: a nationwide study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Multiple sclerosis in stepsiblings: recurrence risk and ascertainment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Conjugal multiple sclerosis: Population-based prevalence and recurrence risks in offspring

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Autoimmune disease in families with multiple sclerosis: a population-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

B-lymphocyte alloantigens associated with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Multiple Sclerosis and High Incidence of a B Lymphocyte Antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

HLA-DQB1 genotype in Sardinian multiple sclerosis: evidence for a key role of DQB1 *0201 and *0302 alleles

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Golli-MBP gene in multiple sclerosis susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

A second major histocompatibility complex susceptibility locus for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

HLA-DRB1 and multiple sclerosis in Malta

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

The inheritance of resistance alleles in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Risk alleles for multiple sclerosis identified by a genomewide study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Variation in interleukin 7 receptor α chain (IL7R) influences risk of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Refining genetic associations in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Axonal transection in the lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Nodal, paranodal and juxtaparanodal axonal proteins during demyelination and remyelination in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Cell death and control of cell survival in the oligodendrocyte lineage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Critical regulation of CD4+ T cell survival and autoimmunity by beta-arrestin 1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Neurofascin as a novel target for autoantibody-mediated axonal injury

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Axonal damage in acute multiple sclerosis lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Semaphorin 3A and 3F: key players in myelin repair in multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Oligodendrocyte regeneration in the adult rodent CNS and the failure of this process in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Myelin repair: the role of stem and precursor cells in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Remyelination is extensive in a subset of multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Lack of association between antimyelin antibodies and progression to multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Axonal protection in multiple sclerosis--a particular need during remyelination?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

The restoration of conduction by central remyelination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Familial effects on the clinical course of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Electrically active axons degenerate when exposed to nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Different pathways for iNOS-mediated toxicity in vitro dependent on neuronal maturation and NMDA receptor expression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Disruption of neurofascin localization reveals early changes preceding demyelination and remyelination in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

A role for oligodendrocyte-derived IGF-1 in trophic support of cortical neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular mechanisms: a novel role for oligodendrocyte-derived glial cell line-derived neurotrophic factor.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Trophic factors attenuate nitric oxide mediated neuronal and axonal injury in vitro: roles and interactions of mitogen-activated protein kinase signalling pathways.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Leber's hereditary optic neuropathy mitochondrial DNA mutations in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

The clinical features of Leber's hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Mitochondrial defects in acute multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Homogeneity of active demyelinating lesions in established multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Tissue preconditioning may explain concentric lesions in Baló's type of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

The clinical course of neuromyelitis optica (Devic's syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Revised diagnostic criteria for neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Changes in the clinical phenotypes of multiple sclerosis during the past 50 years in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Role of return migration in the emergence of multiple sclerosis in the French West Indies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

'The marvellous harmony of the nervous parts': the origins of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Plasma exchange for severe attacks of CNS demyelination: predictors of response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Exacerbations of multiple sclerosis in patients treated with gamma interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Overview of azathioprine treatment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Interferons in relapsing remitting multiple sclerosis: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Lack of evidence for use of glatiramer acetate in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Oral fingolimod (FTY720) for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961620-7

7 January 2021

10.1016/S0140-6736(08)61620-7

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

23563

23563

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference